Yong Yu - Genelux Common Senior Development
| GNLX Stock | 3.61 0.01 0.28% |
Executive
Yong Yu is Senior Development of Genelux Common
| Age | 52 |
| Address | 2625 Townsgate Road, Westlake Village, CA, United States, 91361 |
| Phone | 805 267 9889 |
| Web | https://www.genelux.com |
Latest Insider Transactions
Genelux Common Management Efficiency
The company has return on total asset (ROA) of (0.8214) % which means that it has lost $0.8214 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.901) %, meaning that it created substantial loss on money invested by shareholders. Genelux Common's management efficiency ratios could be used to measure how well Genelux Common manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.07 in 2024. Return On Capital Employed is likely to rise to -1.08 in 2024. At this time, Genelux Common's Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 25.4 M in 2024, whereas Net Tangible Assets are likely to drop (31.3 M) in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| David MS | Ikena Oncology | N/A | |
| MSc MBA | NewAmsterdam Pharma | 37 | |
| Linda Arsenault | Amylyx Pharmaceuticals | N/A | |
| Alice PharmD | Inventiva Sa | 53 | |
| Jim Jacobson | NewAmsterdam Pharma | N/A | |
| Andrew Funderburk | Monte Rosa Therapeutics | N/A | |
| Anna Gifford | Compass Therapeutics | N/A | |
| Robyn MA | Acumen Pharmaceuticals | N/A | |
| Douglas Kling | NewAmsterdam Pharma | 51 | |
| Luciana Marques | MoonLake Immunotherapeutics | N/A | |
| Neil CPA | Compass Therapeutics | 57 | |
| Nathalie Harroy | Inventiva Sa | 57 | |
| Pascaline Clerc | Inventiva Sa | 44 | |
| Thomas Dalton | Cingulate | N/A | |
| Tammy Sarnelli | Amylyx Pharmaceuticals | N/A | |
| Keith White | Amylyx Pharmaceuticals | N/A | |
| JD Esq | Acumen Pharmaceuticals | 53 | |
| Nicolas Mosimann | MoonLake Immunotherapeutics | N/A | |
| Harris Rotman | Centessa Pharmaceuticals PLC | N/A | |
| Diana Chung | Terns Pharmaceuticals | N/A | |
| Jeffrey Jasper | Terns Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -2.9 | ||||
| Return On Asset | -0.82 |
Genelux Common Leadership Team
Elected by the shareholders, the Genelux Common's board of directors comprises two types of representatives: Genelux Common inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Genelux. The board's role is to monitor Genelux Common's management team and ensure that shareholders' interests are well served. Genelux Common's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Genelux Common's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ralph BSc, Head Affairs | ||
| Sean JD, General Secretary | ||
| Lourie Zak, Chief Officer | ||
| Joseph Cappello, Chief Officer | ||
| Thomas JD, CEO Chairman | ||
| Caroline Jewett, VP Quality | ||
| Yong Yu, Senior Development | ||
| Pr MD, Chief Officer |
Genelux Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Genelux Common a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.9 | ||||
| Return On Asset | -0.82 | ||||
| Current Valuation | 79.43 M | ||||
| Shares Outstanding | 27 M | ||||
| Shares Owned By Insiders | 21.98 % | ||||
| Shares Owned By Institutions | 22.29 % | ||||
| Number Of Shares Shorted | 2.32 M | ||||
| Price To Book | 5.68 X | ||||
| Price To Sales | 651.09 X | ||||
| Revenue | 170 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| C | Citigroup | |
| CRM | Salesforce | |
| MSFT | Microsoft |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genelux Common. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Genelux Stock please use our How to Invest in Genelux Common guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Complementary Tools for Genelux Stock analysis
When running Genelux Common's price analysis, check to measure Genelux Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genelux Common is operating at the current time. Most of Genelux Common's value examination focuses on studying past and present price action to predict the probability of Genelux Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genelux Common's price. Additionally, you may evaluate how the addition of Genelux Common to your portfolios can decrease your overall portfolio volatility.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |
Is Genelux Common's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genelux Common. If investors know Genelux will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genelux Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.92) | Quarterly Revenue Growth (0.95) | Return On Assets (0.82) | Return On Equity (2.90) |
The market value of Genelux Common is measured differently than its book value, which is the value of Genelux that is recorded on the company's balance sheet. Investors also form their own opinion of Genelux Common's value that differs from its market value or its book value, called intrinsic value, which is Genelux Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genelux Common's market value can be influenced by many factors that don't directly affect Genelux Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Genelux Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if Genelux Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genelux Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.